There are three ongoing clinic trails: NCT02271945 is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + AMP-514 in participants with relapsed or refractory aggressive B-cell lymphomas who have failed 1–2 prior lines of therapy; NCT02013804 is a dose-escalation study to test the safety, tolerability, PK, immunogenicity and anti-tumor activity in adult patients bearing solid tumors; NCT02118337 is a combinational trail to assess the safety and tolerability of AMP-514, with MEDI4736 (Anti-PD-L1 Antibody). The gene discussed is CD274; the disease is B-cell non-Hodgkin lymphoma.